

## **Results of REALITY Trial Reaffirm Safety and Efficacy of TAXUS**

and Orlando, FL (March 6, 2005) -- Boston Scientific Corporation (NYSE: BSX) today welcomed the results of Johnson & Johnson's REALITY clinical trial, which reaffirmed the safety and efficacy of Boston Scientific's TAXUS® Express<sup>2</sup>™ paclitaxel-eluting coronary stent system. Boston Scientific Chief Operating Officer Paul LaViolette today issued the following statement from the annual American College of Cardiology (ACC) scientific session in Orlando, Florida.

"While REALITY failed to meet its primary endpoint, we were particularly pleased to see that it reaffirmed the safety of the TAXUS stent system. As highlighted in today's REALITY presentation at ACC, there were 'no significant differences' in safety endpoints between the Cypher and TAXUS systems, according to the presentation.

"The absence of any significant differences in the safety endpoints within the intent-to-treat patient population once again reaffirms the excellent safety profile of approved drug-eluting stents. The reported early stent thrombosis rates for both arms are well within the previously established safety profile for both technologies.

"The REALITY trial adds to the extensive body of clinical evidence from randomized, controlled trials - encompassing thousands of patients - that reinforces the safety profile of the TAXUS system."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: [www.bostonscientific.com](http://www.bostonscientific.com).

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, commercialization of new technologies, intellectual property, and other factors described in the Company's filings with the Securities and Exchange Commission.

---

<https://news.bostonscientific.com/news-releases?item=58739>